Characterization of an immune-evading doxycycline-inducible lentiviral vector for gene therapy in the spinal cord

F De Winter, I Francos Quijorna, E Burnside, B Hobo, R Eggers, S A Hoyng, H P Mulder, R C Hoeben, E M Muir, E J Bradbury, J Verhaagen

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgaveArtikelWetenschappelijkpeer review

1 Citaat (Scopus)
226 Downloads (Pure)


Gene therapy is a powerful approach to promote spinal cord regeneration. For a clinical application it is important to restrict therapeutic gene expression to the appropriate time window to limit unwanted side effects. The doxycycline (dox)-inducible system is a widely used regulatable gene expression platform, however, this system depends on a bacterial-derived immunogenic transactivator. The foreign origin of this transactivator prevents reliable regulation of therapeutic gene expression and currently limits clinical translation. The glycine-alanine repeat (GAR) of Epstein-Barr virus nuclear antigen-1 protein inhibits its presentation to cytotoxic T cells, allowing virus-infected cells to evade the host immune system. We developed a chimeric transactivator (GARrtTA) and show that GARrtTA has an immune-evading advantage over "classical" rtTA in vivo. Direct comparison of lentiviral vectors expressing rtTA and GARrtTA in the rat spinal cord shows that the GARrtTA system is inducible for 6 doxycycline-cycles over a 47 week period, whereas with the rtTA-based system luciferase reporter expression declines during the 3rd cycle and is no longer re-inducible, indicating that GARrtTA provides an immune-advantage over rtTA. Immunohistochemistry revealed that GARrtTA expressing cells in the spinal cord appear healthier and survive better than rtTA expressing cells. Characterization of the immune response shows that expression of GARrtTA, in contrast to rtTA, does not recruit cytotoxic T-cells to the transduced spinal cord. This study demonstrates that fusion of the GAR domain to rtTA results in a functional doxycycline-inducible transactivator with a clear immune-advantage over the classical rtTA in vivo.

Originele taal-2Engels
Pagina's (van-tot)114120
TijdschriftExperimental Neurology
StatusGepubliceerd - 20 mei 2022


Duik in de onderzoeksthema's van 'Characterization of an immune-evading doxycycline-inducible lentiviral vector for gene therapy in the spinal cord'. Samen vormen ze een unieke vingerafdruk.

Citeer dit